Non-Viral Vectors for Delivery of Nucleic Acid Therapies for Cancer

Kanvinde, Shrey; Kulkarni, Tanmay; Deodhar, Suyash; Bhattacharya, Deep; Dasgupta, Aneesha

doi:10.3390/biotech11010006

Cited by 24 publications

(15 citation statements)

References 160 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The combination of delivering nucleic acid and small-molecular drugs always were regarded as a challenging barrier due to the defined differences of the two types of drugs, especially in their physicochemical properties, including the molecular weight, electrical properties, hydrophilicity or hydrophobicity, and metabolic stability, all of which greatly affect their biodistribution and pharmacokinetic properties 17 , 51 , 52 . Most recent strategies were developed based on these differences and often the best choice was introducing a module for loading the chemotherapeutic agent into the existing carrier for nucleic acid drug.…”

Section: Different Types For Drug Encapsulationmentioning

confidence: 99%

Advanced strategies for nucleic acids and small-molecular drugs in combined anticancer therapy

Qiu¹,

Wu²,

Shi³

et al. 2023

Int. J. Biol. Sci.

View full text Add to dashboard Cite

Cancer has been considered as complex malignant consequence of genetic mutations that control the cellular proliferation, differentiation and homeostasis, thus making tumor treatment extremely challenging. To date, a variety of cargo molecules, including nucleic acids drugs (pDNA, miRNA and siRNA), therapeutic drugs (doxorubicin, paclitaxel, daunomycin and gefitinib) and imaging agents (radioisotopes, fluorescence dyes, and MRI contrast agents) have been regarded as the potential medicines in clinical application. However, non-single therapeutic drug could induce the satisfied clinical results because of tumor heterogeneity and multiple drug resistance and the nanotechnology-based combined therapy is becoming an advanced important mode for enhanced anticancer effects. The review gathers the current advanced development to co-deliver small-molecular drugs and nucleic acids for the anticancer therapy with nanomedicine-based combination. Furthermore, the superiority is definitely presented and the barriers are detail discussed to surmount the clinical challenges. In final, future perspectives in rational direction for combined tumor therapy of drugs and nucleic acids are exhibited.

show abstract

Section: Different Types For Drug Encapsulationmentioning

confidence: 99%

Advanced strategies for nucleic acids and small-molecular drugs in combined anticancer therapy

Qiu¹,

Wu²,

Shi³

et al. 2023

Int. J. Biol. Sci.

View full text Add to dashboard Cite

show abstract

“…This may be due to improvements in their efficiency, safety, stability of gene expression and specificity. Non-viral vectors have a lower testing burden and smaller storage footprint compared to viral vectors [201,202]. Moreover, they are amenable for use in personalized therapies that target patients' personal mutanome [202,203].…”

Section: Non-viral Vectorsmentioning

confidence: 99%

“…Non-viral vectors have a lower testing burden and smaller storage footprint compared to viral vectors [201,202]. Moreover, they are amenable for use in personalized therapies that target patients' personal mutanome [202,203]. These characteristics are important when deciding on a gene correction platform for treating one or a small number of patients.…”

Section: Non-viral Vectorsmentioning

confidence: 99%

Current strategies employed in the manipulation of gene expression for clinical purposes

et al. 2022

View full text Add to dashboard Cite

Abnormal gene expression level or expression of genes containing deleterious mutations are two of the main determinants which lead to genetic disease. To obtain a therapeutic effect and thus to cure genetic diseases, it is crucial to regulate the host’s gene expression and restore it to physiological conditions. With this purpose, several molecular tools have been developed and are currently tested in clinical trials. Genome editing nucleases are a class of molecular tools routinely used in laboratories to rewire host’s gene expression. Genome editing nucleases include different categories of enzymes: meganucleses (MNs), zinc finger nucleases (ZFNs), clustered regularly interspaced short palindromic repeats (CRISPR)- CRISPR associated protein (Cas) and transcription activator-like effector nuclease (TALENs). Transposable elements are also a category of molecular tools which includes different members, for example Sleeping Beauty (SB), PiggyBac (PB), Tol2 and TcBuster. Transposons have been used for genetic studies and can serve as gene delivery tools. Molecular tools to rewire host’s gene expression also include episomes, which are divided into different categories depending on their molecular structure. Finally, RNA interference is commonly used to regulate gene expression through the administration of small interfering RNA (siRNA), short hairpin RNA (shRNA) and bi-functional shRNA molecules. In this review, we will describe the different molecular tools that can be used to regulate gene expression and discuss their potential for clinical applications. These molecular tools are delivered into the host's cells in the form of DNA, RNA or protein using vectors that can be grouped into physical or biochemical categories. In this review we will also illustrate the different types of payloads that can be used, and we will discuss recent developments in viral and non-viral vector technology.

show abstract

“…For instance, reducing the chain length, decreasing the hydrophobicity, or enhancing the charge density of polymer would reduce nanocarriers’ stability but increase the chances of nucleic acid release. Otherwise, the nucleic acids can hardly be released, and the stability is compromised ( Kanvinde et al, 2022 ).…”

Section: Nucleic Acids As the Cargo Of Np Delivery Systemsmentioning

confidence: 99%

Nucleic acid strategies for infectious disease treatments: The nanoparticle-based oral delivery route

et al. 2022

View full text Add to dashboard Cite

Therapies based on orally administrated nucleic acids have significant potential for the treatment of infectious diseases, including chronic inflammatory diseases such as inflammatory bowel disease (IBD)-associated with the gastrointestinal (GI) tract, and infectious and acute contagious diseases like coronavirus disease 2019 (COVID-19). This is because nucleic acids could precisely regulate susceptibility genes in regulating the pro- and anti-inflammatory cytokines expression related to the infections. Unfortunately, gene delivery remains a major hurdle due to multiple intracellular and extracellular barriers. This review thoroughly discusses the challenges of nanoparticle-based nucleic acid gene deliveries and strategies for overcoming delivery barriers to the inflammatory sites. Oral nucleic acid delivery case studies were also present as vital examples of applications in infectious diseases such as IBD and COVID-19.

show abstract

Non-Viral Vectors for Delivery of Nucleic Acid Therapies for Cancer

Cited by 24 publications

References 160 publications

Advanced strategies for nucleic acids and small-molecular drugs in combined anticancer therapy

Advanced strategies for nucleic acids and small-molecular drugs in combined anticancer therapy

Current strategies employed in the manipulation of gene expression for clinical purposes

Nucleic acid strategies for infectious disease treatments: The nanoparticle-based oral delivery route

Contact Info

Product

Resources

About